Recently, a phase I clinical trial of DNX-2401 treating patients with recurrent GBM suggested increased numbers of macrophages and proinflammatory factors, including IL-6 and TNF-α, in posttreatment tumor specimens [132]. This evidence concerns the gene IL6 and glioblastoma.